| ¿µ¹® | parenteral administration of drugs | ÇÑ±Û | ºñ°æ±¸Àû ¾àǰÅõ¿© |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ÅëÇÏÁö ¾Ê´Â ´Ù¾çÇÑ ¾àǰÅõ¿© ¹æ¹ýÀ» ¸»ÇÔ. ÁÖ»ç±â¸¦ ÀÌ¿ëÇÑ´Ù. 1)ÇÇÇÏÁÖ»ç: subcutaneous injection-ÇǺΠ¹ØÀ¸·Î ÁÖ»çÇÏ´Â °Í. ´ë°³ ÆÈÀÇ Áß°£ºÎ¿¡ ÁÖ»çÇÑ´Ù. 2)ÁøÇdz»ÁÖ»ç: intradermal injection-¾ã°Ô Âñ·¯¼ ÁøÇdz»¿¡ ÁÖ»çÇÑ´Ù. ÁÖ·Î ¾Ë·¯Áö ȯÀÚÀÇ Ç׿ø°Ë»ç¿¡ ÀÌ¿ëÇÑ´Ù. 3)±ÙÀ°³»ÁÖ»ç: intramuscular injection-À§ÆÈÀ̳ª, ȤÀº ¾ûµ¢ÀÌ ºÎÀ§¿¡ ÁÖ»çÇÑ´Ù. À̰ÍÀº ÁÖ·Î ÇǺο¡ ÀÚ±ØÀÌ ½ÉÇÑ ¾àÁ¦³ª ȤÀº õõÈ÷ ÀÛ¿ëÇÏ´Â ¾àÁ¦¸¦ ¸¹ÀÌ ÁÖ»çÇÒ ¶§ »ç¿ëÇÑ´Ù. 4)Ç÷°üÁÖ»ç: intravenous(IV) injection-Á¤¸ÆÀ» ÅëÇØ ÁÖ»çÇÑ´Ù. ¾î´À Á¤¸ÆÀ̳ª °¡´ÉÇÏÁö¸¸, ´ë°³ ÆÈ¶ÒÀ̳ª ¹ß µîÀÇ Á¤¸ÆÀ» ÀÌ¿ëÇÑ´Ù. ºü¸¥ Ä¡·áÈ¿°ú¸¦ º¸±â À§ÇØ »ç¿ëÇÑ´Ù. À̶§ ÇǺο¡ ÀÚ±ØÀ» ÁÖ´Â ¾àÁ¦À̸é, »õÁö ¾Êµµ·Ï Á¶½ÉÇØ¾ß ÇÑ´Ù. 5) ¼ö¸·°³»ÁÖ»ç: intrathecal injection-µÎ°³³ª ô¼ö°³»¿¡ ÁÖ»çÇÒ ¶§ ÀÌ¿ëÇÑ´Ù. 6)°³»ÁÖ»ç: intracavitary injection-°ø°£À¸·Î µÈ ºÎÀ§¿¡ ÁÖ»çÇÑ´Ù. ¿¹¸¦ µé¾î º¹ºÎ°ø°£À̳ª Èä°³»¿¡ ÁÖ»çÇÏ¿© »ç¿ëÇÑ´Ù. |
||
| ¿µ¹® | rectal administration of drugs | ÇÑ±Û | ¾à¹°ÀÇ °ðâÀÚÁ¾à½Ä Åõ¿© |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ÅëÇØ ¸ÔÀº ¾à¹°Àº Èí¼öµÈ ÈÄ °£À» °ÅÃÄ º´º¯ºÎÀ§·Î ¿î¹ÝµÈ´Ù. µû¶ó¼ °£¿¡¼ ´ë»ç°¡ µÇ¾î ¾à¹°·Î¼ÀÇ È¿°ú°¡ ¾ø¾îÁú °¡´É¼ºÀÌ ÀÖÀ» »Ó ¾Æ´Ï¶ó °£¿¡ µ¶¼ºÀÛ¿ëÀ» ÀÏÀ¸Å³ ¼öµµ ÀÖ´Ù. ÀÌ·¯ÇÑ ´ÜÁ¡À» º¸¿ÏÇϱâÀ§ÇØ °£À» ÅëÇÏÁö ¾Ê°í À绡¸® Èí¼öµÇ¾î º´º¯À¸·Î °¥ ¼ö ÀÖ´Â ¹æÆíÀ¸·Î Á÷ÀåÁ¾àÀ» »ç¿ëÇÑ´Ù. Á÷ÀåÀÇ Á¤¸ÆÈ帧Àº °£À» °ÅÄ¡Áö ¾Ê°í Á÷Á¢ ÇÏ´ëÁ¤¸ÆÀ» ÅëÇØ ¿ì½É¹æÀ¸·Î Èê·¯µé±â ¶§¹®ÀÌ´Ù. |
||
| ¿µ¹® | side effects of drugs | ÇÑ±Û | ¾à¹°ÀÇ ºÎÀÛ¿ë |
|---|---|---|---|
| ¼³¸í | ¾àÀ» »ç¿ëÇÒ ¶§ ±â´ëÇÏ´Â È¿°ú ¿Ü¿¡ ´Ù¸¥ Àå±â¿¡¼ ³ªÅ¸³ª´Â ¿øÄ¡ ¾Ê´Â È¿°ú¸¦ ÃÑĪÇÏ´Â ¸»ÀÌ´Ù. ¿¹¸¦ µé¾î Ç÷¾ÐÀ» ³·Ãß±â À§ÇØ Ç×°íÇ÷¾ÐÁ¦¸¦ »ç¿ë ½Ã, Ç÷¾ÐÀÌ ¶³¾îÁö´Â µ¿½Ã¿¡ ±â°üÁöÀÇ ¼öÃàÀÌ ÀϾ´Â Çö»ó. |
||
| ¿µ¹® | infectious disease | ÇÑ±Û | °¨¿°º´ |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º·ÎºÎÅÍ ±â»ýÃæ Å©±â±îÁöÀÇ »ý¹°À» ¿øÀÎÀ¸·Î ÇÏ´Â º´. ¿øÀÎÀº Á¢ÃËÀü¿°¼ºÀ̸ç, º´¿ø¿¡¼ °¨¿°µÇ´Â °æ¿ìµµ ÀÖ´Ù. °¨¿°À» ¿øÀαտ¡ µû¶ó ºÐ·ùÇÏ¸é ¹ÙÀÌ·¯½º, ¼¼±Õ, Ŭ¶ó¹Ìµð¾Æ, ¸®ÄÏÂ÷, ¹ÌÄÚ¹ÚÅ׸®¿ò, °õÆÎÀÌ, ¿øÃæ, À±Ãæ, ¿ÜºÎ±â»ýÃæ °¨¿°À¸·Î ³ª´ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | hypertensive heart disease | ÇÑ±Û | °íÇ÷¾Ð½ÉÀ庴 |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾Ð¿¡ ÀÇÇØ¼ »ý±â´Â ½ÉÀ庴. °íÇ÷¾Ð½ÉÀ庴À̶ó´Â Áø´ÜÀ» ºÙÀ̱â À§Çؼ´Â ÃÖ¼ÒÇÑ ´ÙÀ½°ú °°Àº Á¶°ÇÀÌ ºÎÇյǾî¾ß Çϴµ¥, ù° ½ÉÀåÇ÷°ü°è¿¡ ½ÉÀ庴À» À¯¹ßÇÒ ¼ö ÀÖÀ» ¸¸ÇÑ ´Ù¸¥ º´º¯ÀÌ ¾øÀÌ ÁÂ½É½Ç ºñ´ë°¡ ÀÖ¾î¾ß Çϸç, µÑ° °íÇ÷¾ÐÀ» ¾Î¾Ò´Ù´Â º´·ÂÀÌ ÀÖ¾î¾ß ÇÑ´Ù. ÁÖ·Î °íÇ÷¾Ð¿¡ ÀÇÇÑ ½ÉÀ庴Àº Ãʱ⿡´Â Á½ɽÇÀÌ ºñÈĶó´Â °ÍÀ¸·Î Ư¡µÇ¾îÁø´Ù. Áï Ç÷¾ÐÀÌ ³ôÀ¸¹Ç·Î Ç÷¾×À» ¼øÈ¯½Ã۱â À§Çؼ´Â ±×¸¸Å ½ÉÀåÀÇ Ç÷¾×À» º¸³»´Â ÈûÀÌ ÁÁ¾Æ¾ß ÇÑ´Ù. ±× ÈûÀ» ¾ò±âÀ§Çؼ´Â ½É±ÙÀÇ ºñÈİ¡ ÇÊ¿ä·Î ÇÏ¿© ÁÂ½É½Ç ±ÙÀ°ÀÇ ºñÈİ¡ »ý±ä´Ù. ±×¸®°í °íÇ÷¾ÐÀÌ Áö¼ÓÀÌ µÉ °æ¿ì¿¡´Â °á±¹ ½ÉÀåÀÌ Á¦ ±¸½ÇÀ» ÇÏÁö ¸øÇÏ°í ÆßÇÁ·Î¼ÀÇ ±â´ÉÀ» ÀÒ¾î¹ö¸®°Ô µÇ¾î ½ÉÀå±â´É»ó½Ç¿¡ ºüÁö°Ô µÈ´Ù. |
||
| DMARDs | Disease Modifying Anti-Rheumatic Drugs |
|---|---|
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
| HD | Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ... |
| MD | Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major... |
| DMARD | Disease Modifying Antirheumatic Drugs |
|---|---|
| DMF | Dose Modifying Factor |
| RAMP | receptor activity modifying protein |
| ATD | Antithyroid drugs |
| NSAID | Non Steroid Anti-Inflammatory Drugs |
Kugelberg-Welander disease ±Ù À§ÃàÁõÀÇ À¯Àü¼º ¿¬¼ÒÇüÀ¸·Î¼ º¸Åë »ó¿°»öü¼º ¿¼º ÇüÁú·Î À¯ÀüµÈ´Ù. ô¼ö Àü°¢ÀÇ º´º¯ÀÌ ±× ¿øÀÎÀÌ´Ù.
kukuruku ¿øÀÎ ºÒ¸íÀ̸ç, ³ªÀÌÁö¸®¾Æ¿¡¼ º¼ ¼ö ÀÖ´Â ÁúȯÀ¸·Î, ¿
| ischemia-modifying factors | Various factors that play a role in determining the extent of necrosis with cerebral stroke; these include blood viscosity and osmolality, the blood pressure, and the anatomy of the neck and intracranial arteries. (05 Mar 2000) |
|---|---|
| antirheumatic | 1. Denoting an agent which suppresses manifestations of rheumatic disease; usually applied to anti-inflammatory agents or agents that are capable of delaying progression of the basic disease process in inflammatory arthritis. 2. An agent possessing such properties (e.g., gold compounds). (05 Mar 2000) |
| antirheumatic agents | Drugs that are used to treat rheumatoid arthritis. (12 Dec 1998) |
| antirheumatic agents, gold | Gold salts that are effective in the therapy of rheumatoid arthritis. These compounds usually do not have analgesic activity. Since these compounds are poorly absorbed from the intestinal tract, they are usually given intramuscularly. (12 Dec 1998) |
| veterinary drugs | Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the united states most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products. (12 Dec 1998) |
| cytotoxic drugs | <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells. See: chemotherapy. (13 Nov 1997) |
| psychotropic drugs | A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquillising agents (including the antipsychotics and anti-anxiety agents). (12 Dec 1998) |
| neuroleptic drugs | Literally nerve seising: used of chlorpromazine like drugs. Antagonise the effects of dopamine. Origin: Gr. Lepsis = a taking hold (18 Nov 1997) |
| street drugs | Drugs obtained and often manufactured illegally for the subjective effects they are said to produce. They are often distributed in urban areas, but are also available in suburban and rural areas, and tend to be grossly impure and may cause unexpected toxicity. (12 Dec 1998) |
| designer drugs | Drugs designed and synthesised, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are mptp (a reverse ester of meperidine), mda (3,4-methylenedioxyamphetamine), and mdma (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines. (12 Dec 1998) |
| drugs, chinese herbal | Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesised compounds manufactured in china. (12 Dec 1998) |
| drugs, essential | Drugs considered essential to meet the health needs of a population as well as to control drug costs. (world health organization action programme on essential drugs, 1994, p3) (12 Dec 1998) |
| drugs, generic | Drugs whose drug name is not protected by a trademark. They may be manufactured by several companies. (12 Dec 1998) |
| drugs, investigational | Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (treatment ind). The main heading includes drugs under investigation in foreign countries. (12 Dec 1998) |
| drugs, non-prescription | Drugs that can be sold legally without a prescription. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|